AN2 Therapeutics, Inc.

The momentum for this stock is not very good. AN2 Therapeutics, Inc. is not very popular among insiders. AN2 Therapeutics, Inc. is a mediocre stock to choose.

News

AN2 Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Business Wire AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced...\n more…

AN2 Therapeutics adopts limited duration stockholder rights plan

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

AN2 Therapeutics Adopts Limited Duration Stockholder Rights Plan

Video: Thursday 8/15 Insider Buying Report: ANTX, WRBY

Market News Video As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let's look at two noteworthy recent insider buys...\n more…

Strong Cash Reserves and Promising Pipeline Justify Buy Rating for AN2 Therapeutics

TipRanks Financial Blog Analyst Roy Buchanan of JMP Securities reiterated a Buy rating on AN2 Therapeutics, Inc. (ANTX - Research Report), retaining the price target of $3...\n more…

ANTX Stock Earnings: AN2 Therapeutics Beats EPS for Q2 2024

InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nANTX stock results show that AN2 Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.\nThe post ANTX...\n more…